

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: SOL Global Investments Corp. (the “Company” or “Issuer”).

Trading Symbol: SOL

Number of Outstanding Listed Securities: 53,217,538

Date: June 3, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website. This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

On May 3, 2021, the Issuer increased its position in Captor Capital Corp. (“Captor”) (CSE:CPTR) to 16.32%, through the acquisition of 4,105,263 units in the capital of Captor (“Units”) in connection with a non-brokered private placement of Captor completed on April 30, 2021 (the “Transaction”). The completion of the Transaction resulted in a greater than 2.0% increase in the security holding percentage of common shares in the capital of Captor (“Common Shares”) reported since the last early warning report filed by the Company on April 12, 2021.

On April 28, 2021, the Issuer acquired 4,105,263 Units at a price of \$0.95 per Unit. Each Unit is comprised of one (1) Common Share and one-half of one (1/2) Common Share purchase warrant (each, a “Warrant”) exercisable at \$1.20 for a period of 24 months. Immediately prior to the completion of the Transaction, Issuer owned 4,238,200 Common Shares, representing approximately 10.97% of the issued and outstanding Common Shares on a non-diluted basis.

Following the completion of the Transaction, the Issuer now owns 8,343,463 Common Shares representing approximately 16.32% of the issued and outstanding Common Shares on a nondiluted basis. Together with the 2,052,632 Warrants acquired by the Company in connection with the private placement, Issuer now beneficially owns approximately 19.55% of Captor on a partially diluted basis with an average-cost-base on Captor is \$0.93 per Common Share. The completion of the Transaction resulted in an approximately 5.4% increase in the Company's security holding percentage of the issued and outstanding Common Shares on a non-diluted basis.

On May 10, 2021, the Issuer announced that it had purchased an aggregate of 1,538,800 common shares in the capital of the Company ("Common Shares") during the current purchase cycle pursuant to the Company's previously announced normal course issuer bid ("NCIB"), which commenced on March 31, 2021. A maximum of 2,737,805 Common Shares may be purchased pursuant to the NCIB, representing approximately 5% of the issued and outstanding Common Shares as at the time of the commencement of the NCIB. To date, an aggregate of 1,538,800 Common Shares have been purchased by the Company under the NCIB through the facilities of the Canadian Securities Exchange at an average purchase price of \$4.3831 per share. There are 53,217,538 Common Shares issued and outstanding as of the current date. An additional 1,199,005 Common Shares may be purchased by the Company under the NCIB. The Company intends to repurchase the full 5% and will be updating the market on the progress of its NCIB on a monthly basis. The NCIB is expected to terminate on March 31, 2022, or such earlier date at the discretion of the Company or upon the completion of the purchase of the maximum number of Common Shares under the NCIB.

On May 10, 2021, Wesana Health Inc. ("Wesana") commenced trading on the CSE under the ticker CSE:WESA. Issuer currently owns 9.6% of the company's equity. Wesana is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.

- 2. Describe the acquisition of new customers or loss of customers.**
None noted.
- 3. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**
None noted.
- 4. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**
None noted.
- 5. Report on any labour disputes and resolutions of those disputes if applicable.**
None noted.
- 6. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None noted.

- 7. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

None noted.

- 8. Provide details of any securities issued and options or warrants granted.**

None noted.

- 9. Provide details of any loans to or by Related Persons**

None noted.

- 10. Provide details of any changes in directors, officers or committee members.**

None noted

- 11. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

None noted.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: June 3, 2021.

Paul Kania
Name of Director or Senior Officer
/s/ "Paul Kania"
Signature
CFO
Official Capacity

Issuer Details Name of Issuer SOL Global Investments Corp.	For Month End May 2021	Date of Report YY/MM/D 21/06/03
Issuer Address 5600-100 King St. West		
City/Province/Postal Code Toronto, ON, M5X 1C9	Issuer Fax No. ()	Issuer Telephone No. (212) 729-9208
Contact Name Paul Kania	Contact Position CFO	Contact Telephone No. (212) 729-9208
Contact Email Address info@solglobal.com	Web Site Address https://solglobal.com/	